The SENTINEL Plus quality improvement framework encourages practices to prioritise targeted reviews for those asthma patients at highest risk - such as patients issued six or more short-acting beta 2 agonist (SABA) inhalers in the past year - while working towards reviewing all patients prescribed three or more SABA inhalers annually.
It is important to embed an ongoing practice of identifying and addressing SABA overuse to ensure that patients have their asthma treatment optimised in line with guideline recommendations.
